Regeneron Pharmaceuticals (REGN) News Today $526.19 +8.59 (+1.66%) As of 03:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Atwood & Palmer Inc. Sells 1,709 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Atwood & Palmer Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,974 shares of the biopharmaceutical comJune 10 at 8:37 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Avanza Fonder ABAvanza Fonder AB lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 8,899 shares of the biopharmaceutical company's stock after selling 1,509 shareJune 10 at 7:59 AM | marketbeat.comRegeneron Pharma Shares Rise Over 3% After Key SignalJune 10 at 7:48 AM | benzinga.comTounjian Advisory Partners LLC Purchases Shares of 1,042 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Tounjian Advisory Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,042 shares of the biopharmaceutical company's stock, valued atJune 10 at 5:59 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Miracle Mile Advisors LLCMiracle Mile Advisors LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 68.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,366 shares of the biopharmaceutical company's stJune 10 at 4:30 AM | marketbeat.comJPMorgan Chase & Co. Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $800.00June 10 at 1:51 AM | americanbankingnews.comRegeneron Pharmaceuticals (REGN) Price Target Lowered by JP Morgan | REGN Stock NewsJune 9 at 1:18 PM | gurufocus.comRegeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference TranscriptJune 9 at 12:44 PM | seekingalpha.comJPMorgan Chase & Co. Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock PriceJPMorgan Chase & Co. decreased their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday.June 9 at 11:50 AM | marketbeat.comTB Alternative Assets Ltd. Purchases New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)TB Alternative Assets Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,158 shares of the biopharmaceuJune 8 at 5:41 AM | marketbeat.comMerit Financial Group LLC Has $1.03 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Merit Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 87.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,629 shares of the biJune 8 at 4:05 AM | marketbeat.comRegeneron Pharmaceuticals Inc (REGN) Announces Promising Results from Dupixent Trial in Atopic ...June 8 at 12:28 AM | gurufocus.comRegeneron Pharmaceuticals Inc (REGN) Announces Promising Results from Dupixent Trial in ...June 7 at 7:43 PM | gurufocus.comDupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of ColorJune 7 at 6:30 PM | globenewswire.comLake Hills Wealth Management LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Lake Hills Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 616 shares of the biopharmaceutical company's stock, valued at approximatelyJune 7 at 8:09 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (REGN): A Bull Case TheoryJune 6, 2025 | insidermonkey.comProcyon Advisors LLC Purchases 2,992 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Procyon Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 86.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,473 shares of tJune 6, 2025 | marketbeat.comIntellectus Partners LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Intellectus Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 92.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,033 shares of the biopharmaceuticJune 6, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 763 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Hennion & Walsh Asset Management Inc. decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 24.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,343 shares of the bioJune 6, 2025 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year Low on Analyst DowngradeRegeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low Following Analyst DowngradeJune 5, 2025 | marketbeat.comUBS Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $560.00UBS Group reduced their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a research report on Thursday.June 5, 2025 | marketbeat.comLmcg Investments LLC Buys 10,110 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Lmcg Investments LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 231.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,481 shares of the biopharmaceutical company's stJune 5, 2025 | marketbeat.comWhy Regeneron Is Falling And Why You Should Avoid ItJune 4, 2025 | benzinga.comRegeneron reports early data in mid-stage trial of obesity treatmentJune 4, 2025 | msn.comBMO Capital Markets Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $600.00June 4, 2025 | americanbankingnews.comCitigroup Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $650.00June 4, 2025 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $755.00 at Morgan StanleyJune 4, 2025 | americanbankingnews.comRegeneron's weight-loss drug helps patients on Wegovy preserve muscleJune 3, 2025 | msn.comRegeneron Pharmaceuticals, Inc. (REGN)’s Weight-Loss Drug Aids Muscle Preservation in Wegovy UsersJune 2, 2025 | insidermonkey.comRegeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500June 2, 2025 | msn.comREGN Stock Undervalued At $500?June 2, 2025 | forbes.comCitigroup Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock PriceCitigroup dropped their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday.June 2, 2025 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Given New $600.00 Price Target at BMO Capital MarketsBMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a report on Monday.June 2, 2025 | marketbeat.comMorgan Stanley Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $755.00Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a report on Monday.June 2, 2025 | marketbeat.comWoodstock Corp Has $4.51 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Woodstock Corp lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 52.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,115 shares of the biopharmaceutical company's stoJune 2, 2025 | marketbeat.comKymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.June 2, 2025 | barrons.comRegeneron Pharmaceuticals Inc (REGN) Announces Promising Interim Results from Phase 2 COURAGE ...June 2, 2025 | gurufocus.comRegeneron's weight-loss drug helps preserve muscle mass in studyJune 2, 2025 | reuters.comRegeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor AgonistJune 2, 2025 | globenewswire.comBaker Tilly Wealth Management LLC Purchases 641 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Baker Tilly Wealth Management LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 124.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,155 shares of the biopharmacJune 2, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Czech National BankCzech National Bank boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 24,164 shares of the biopharmaceutical company's stock after purchasing an additional 1,338June 2, 2025 | marketbeat.comRhumbline Advisers Has $109.83 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Rhumbline Advisers raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 173,167 shares of the biopharmaceutical company's stock after buying an additional 2June 2, 2025 | marketbeat.comWhy Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last WeekJune 2, 2025 | msn.comRegeneron Pharmaceuticals Unusual Options Activity For May 30June 1, 2025 | nasdaq.comGAMMA Investing LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 89,825.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 815,620 sharesJune 1, 2025 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Hold Rating by Royal Bank of CanadaJune 1, 2025 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Sets New 1-Year Low - Time to Sell?June 1, 2025 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab ResultsMay 31, 2025 | insidermonkey.comRegeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Libtayo in ...May 31, 2025 | gurufocus.comRegeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Libtayo in ...May 31, 2025 | gurufocus.com Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Media Mentions By Week REGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.440.68▲Average Medical News Sentiment REGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼2931▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News Exelixis News BioMarin Pharmaceutical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsA major regulatory shift is scheduled to take effect this July — and it could have serious implications for yo...Monetary Gold | Sponsored“Biggest Social Security Change Ever”The Financial Times called this new Trump initiative "a big pot of money for the American people." And The Mot...InvestorPlace | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy REGN Stock Free REGN Stock Alerts